RT Journal Article
SR Electronic
T1 Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.181185
DO 10.3899/jrheum.181185
A1 Kathleen M.  Andersen
A1 Ayano Kelly
A1 Anne Lyddiatt
A1 Clifton O.  Bingham III
A1 Vivian P.  Bykerk
A1 Adena Batterman
A1 Joan Westreich
A1 Michelle K.  Jones
A1 Marita Cross
A1 Peter M.  Brooks
A1 Lyn March
A1 Beverley Shea
A1 Peter Tugwell
A1 Lee S.  Simon
A1 Robin Christensen
A1 Susan J.  Bartlett
YR 2019
UL http://www.jrheum.org/content/early/2019/04/09/jrheum.181185.abstract
AB Objective The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease. Methods International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees. Results Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence. Conclusion Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.